Meeting
2020 ASCO Virtual Scientific Program
A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).
Authors
Anna M. Varghese
Memorial Sloan Kettering Cancer Center, New York, NY
Anna M. Varghese , Celina Ang , Christopher J. Dimaio , Milind M. Javle , Martin Gutierrez , Nirit Yarom , Salomon M. Stemmer , Talia Golan , Ravit Geva , Valeriya Semenisty , Iyad Khamaysi , Rosario Ligresti , Shay Rotkopf , Racheli Gabai-Malka , Eithan Galun , Amotz Shemi , Mark Schattner , Eileen Mary O'Reilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT01676259
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4672)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4672
Abstract #
TPS4672
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.
First Author: Andrew Oar
Poster
2023 ASCO Annual Meeting
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
First Author: Aaron Ciner
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Depth of response in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory subgroup analysis of JCOG1407.
First Author: Taro Shibuki
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical significance of CA125 in unresectable pancreatic cancer treated with first-line chemotherapy.
First Author: Iori Motoo